EVO301
Atopic Dermatitis
Key Facts
About Evommune
Evommune is a clinical-stage biotech focused on evolving immunology by developing innovative oral therapies for chronic inflammatory diseases with significant unmet need. The company is led by industry veterans and is advancing a pipeline of two primary candidates, EVO756 (targeting MRGPRX2) and EVO301 (targeting IL-18), across multiple indications. Recent milestones include positive Phase 2a data for EVO301 in atopic dermatitis and a $125 million private placement in early 2026 to fund ongoing clinical development.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech focused on evolving immunology by developing innovative oral therapies for chronic inflammatory diseases with significant unmet need. The company is led by industry veterans and is advancing a pipeline of two primary candidates, EVO756 (targeting MRGPRX2) and EVO301 (targeting IL-18), across multiple indications. Recent milestones include positive Phase 2a data for EVO301 in atopic dermatitis and a $125 million private placement in early 2026 to fund ongoing clinical development.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Phase 3 |
| Dupixent | Sanofi | Commercial |
| ASP2408 | Astellas Pharma | Phase 2 |
| KW-6356 | Kyowa Kirin | Phase 2 |
| KHK4083 | Kyowa Kirin | Phase 2 |
| Opzelura (ruxolitinib cream) | Ono Pharmaceutical | Approved |
| ONO-7913 | Ono Pharmaceutical | Phase 2 |
| KT-474 | Kymera Therapeutics | Phase 2 |
| GRC 27864 | Glenmark Pharmaceuticals | Phase 2 |
| ARQ-234 | Arcutis Biotherapeutics | Preclinical/Phase 1 |
| STAR-0310 | BioCryst Pharmaceuticals | Phase 1 |
| Rezpegaldesleukin | Nektar Therapeutics | Phase 2b |